Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.

Abstract

OBJECTIVE:

To assess the efficacy, safety and acceptability of cyclic medroxyprogesterone acetate (MPA) compared to continuous MPA for treatment of endometrial hyperplasia (EH) without atypia.

MATERIALS AND METHODS:

A prospective observational study conducted on premenopausal women with EH without atypia (n = 80) who were randomly assigned into two groups; 40 patients received cyclic 15 mg MPA and 40 patients received continuous 15 mg MPA. Follow-up endometrial sampling was done after 6 months. Primary outcome measure was regression of hyperplasia. Secondary outcome measures include side effects and patient acceptability.

RESULTS:

There was no significant difference between the two groups regarding regression of endometrial hyperplasia (90 % in the cyclic MPA group in comparison to 82.5 % in the continuous MPA group with p value >0.05). There was a significant higher women suffering from nausea, acne and menstrual changes in the continuous MPA group (p value <0.05). Cyclic MPA regimen was more acceptable to the patients in comparison to continuous MPA intake.

CONCLUSIONS:

Cyclic MPA regimen seems a safer and more acceptable therapy in comparison to continuous MPA regimen in patients with endometrial hyperplasia without atypia. Larger studies are warranted to confirm these results.

• Authors: Mohamed Emarh
• Journal: Archives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 292 Issue 6 Pg. 1339-43 (Dec 2015) ISSN: 1432-0711 [Electronic] Germany
• PMID: 26015309 (Publication Type: Journal Article, Observational Study, Randomized Controlled Trial)

Chemical References

• Antineoplastic Agents, Hormonal
• Medroxyprogesterone Acetate

Topics

• Administration, Oral
• Adult
• Antineoplastic Agents, Hormonal (administration & dosage, therapeutic use)
• Biopsy
• Endometrial Hyperplasia (drug therapy, pathology)
• Endometrium
• Female
• Follow-Up Studies
• Humans
• Medroxyprogesterone Acetate (administration & dosage, therapeutic use)
• Premenopause
• Prospective Studies
• Treatment Outcome
• Young Adult